An event is serious (based on the ICH definition) when the patient outcome is:
* congenital anomaly
* other medically important event
In a study, three women aged 43-60 years were described, who developed psoriatic alopecia of scalp [not all time to reactions onsets stated] following treatment with adalimumab, mercaptopurine [6-mercaptopurine], infliximab, leflunomide, ciclosporin [cyclosporine], ustekinumab, apremilast, methotrexate, secukinumab or abatacept [routes and dosages not stated].
Case 1: A 60-year-old woman developed psoriatic alopecia of scalp while receiving treatment with adalimumab and mercaptopurine. The woman, who had severe Crohn's disease, was receiving treatment with adalimumab and mercaptopurine for the last three years. After two years into the treatment, she presented with itching and scaling of scalp. Initially, her itching and scaling of scalp were presumably diagnosed as seborrheic...